Tuesday, November 17, 2026

MEDITWIN collaborates with French companies and organizations on technology! Virtual Twin in Medical Practice and Improved Quality of Care

Dassault Systèmes announced on December 11, 2023 the MEDITWIN consortium, formed in the presence of French President Emmanuel Macron! The MEDITWIN consortium consists of seven university hospital laboratories, the University Hospital of Nantes, several start-ups, and Dassault Systèmes, and will contribute to improving the quality of treatment and nursing care by providing a virtual twin to the medical field to make healthcare safer and more accessible to all.
*This article is a Japanese reference translation of a release issued on January 24, 2024 local time in Vérigie-Villacoubray, France.

Creating new standards of medical care and providing important learning opportunities for the advancement of medicine

Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA, "Dassault Systèmes") announced today that the MEDITWIN consortium, formed in the presence of French President Emmanuel Macron on December 11, 2023 The MEDITWIN Consortium was formed in the presence of French President Emmanuel Macron on December 11, 2023.

The details of the consortium were announced on December 14 at the PariSanté Campus, a digital health development center located in the 15th arrondissement of Paris, in the presence of French Industry Minister Laurent Lescure.

The MEDITWIN consortium is composed of seven university hospital laboratories (IHU), the University Hospital of Nantes (CHU), the French National Institute for Informatics and Automatic Control (Inria), several startups, and Dassault Systèmes MEDITWIN is committed to providing a virtual twin to the medical field, thereby to improve the quality of treatment and nursing care in order to make healthcare safer and more accessible to all.

The MEDITWIN project will provide a virtual twin of organ, metabolic, and cancerous tissue, personalized and created for each patient, for better diagnosis and treatment. By utilizing MEDITWIN, physicians will be able to simulate a patient's prognosis.

Based on this virtual twin, the company plans to develop seven medical modalities in the fields of neurology, cardiovascular, and oncology, and to deploy virtual healthcare products utilizing telemedicine on the industrial Sovereign Cloud platform.

MEDITWIN draws on the expertise of world-leading companies and organizations in their respective fields, led by the 14 founding members of the consortium, and 11 project teams. The consortium includes Dassault Systèmes, an industry leader, seven university hospital laboratories with high standards in medicine and science, the Thoracic Diseases Laboratory of the University Hospital of Nantes, as well as four start-ups: inHEART, codoc, Qairnel and Neurometers, and the French National Institute for Informatics and Automatic Control (Inria).

In the aviation and mobility industries, virtual twins have made great strides in terms of safety, quality, environmental footprint, and cost efficiency, making them indispensable assets today. In virtual twins for the healthcare industry, such as Dassault Systèmes' Living Heart and Living Brain projects, and the Prioritized Research Program (PEPR) for digital medicine, a joint initiative between Inria and INSERM, the French National Institute for Health and Medical Research, the wealth of experience accumulated by participating partners has been used to develop MEDITWINs. MEDITWIN is based on the wealth of experience accumulated by participating partners.

MEDITWIN will industrialize, clinically evaluate, and standardize these innovations, deploying standardized technologies and making their benefits available to a wider audience. Incorporating the highest standards of care and nursing care into virtual experiences accessible from around the world will create new standards of care and provide learning opportunities that are critical to the advancement of medicine.

The effectiveness of the virtual twin will be tested on the medical team, the patient, and the health care system, particularly in terms of treatment efficiency, cross-disciplinary decision making, and the effectiveness and safety of medical methods and interventions.

The MEDITWIN initiative is being implemented under a five-year plan from 2024 to 2029, and funding for participating companies in this project is supported by a grant from the French government as part of the "France 2030" investment plan.

Comments from participating companies and organizations

Mr. Bernard Charlès, Member of the Board of Directors, Dassault Systèmes
The industry has been transformed in a more sustainable way by the virtual twin." Today, we are using this technology to better understand the human body and open up new possibilities in medicine. Dassault Systèmes has been a leader in the virtual twin for 40 years. We believe we can leverage our knowledge and expertise to transform the medical field, and our public-private partnership through MEDITWIN is a major step forward in contributing to the future of medicine, bringing together the highest standards of medicine, science, and technology. The Virtual Twin is already available. We will leverage MEDITWIN to standardize and disseminate the virtual twin to help treat a multitude of patients."

Bruno Sportis, CEO, Inria
Inria and Dassault Systèmes, in line with the strategic partnership signed in 2021, are actively collaborating in the area of the virtual twin in healthcare, with a consistent vision of the data sovereignty agenda and healthcare They are actively collaborating on a coherent vision of digital transformation. The MEDITWIN project, launched with the innovative collaboration of Dassault Systèmes, Inria, and the IHU France Alliance, with the support of France 2030, demonstrates our commitment to building a French industry at the forefront of new healthcare challenges, to the benefit of patients."

Fabrice André, Director of IHU PRISM in the Gustave Roussy Institute
PRISM is developing a cancer avatar that models a patient's biological functions to optimize the delivery of care to each patient, and in keeping with that policy, we have joined the MEDITWIN consortium. PRISM can also draw on the expertise of other IHUs and will work closely with them on this interdisciplinary project."

Mr. Pierre Jae, Director, IHU LIRYC
MEDITWIN, an initiative of the seven IHUs, Inria, and Dassault Systèmes, is a public-private partnership that deserves special mention. The consortium is extremely important for patients because it will enable large-scale automation and usher in a new era of preventive medicine, with enormous cost-effectiveness. Ultimately, it will provide a forum for French physicians and researchers to collaborate with world leaders in industry in the field of digital medicine, the future of medical research."

Prof. Didier Mutte, Director, IHU Strasbourg
The virtual twin is essential for the future of medicine," said Dr. Gabriel Bourdieu, President of the IHU France. MEDITWIN is an outstanding project in terms of its goals and challenges, a first for the IHU French Union, and brings together capabilities in interdisciplinary biomedical research that are unique in the world. It brings together competencies in interdisciplinary biomedical research unparalleled anywhere in the world. By working closely with two of its founding member institutions (Inria and the University Hospital of Strasbourg), MEDITWIN will be a powerful catalyst for IHU Strasbourg to improve the quality of minimally invasive treatments for metastatic colorectal cancer."

Prof. Michel Pak, Head of Department IV, Department of Ophthalmology, IHU FOReSIGHT and Director, 15-20 National Hospital Clinical Research Center
The integration of IHU FOReSIGHT into the MEDITWIN consortium will enable the large-scale development of a virtual twin of retinal microcirculation, optimized detection and tracking of brain and cardiovascular diseases from a quantitative perspective, and the first quantitative microcirculatory biomarkers. iHU FOReSIGHT, in collaboration with French high-tech companies and research institutes, has developed an innovative capillary imaging expertise that employs France's world-class adaptive optics technology for retinal imaging. This globally unique technique, which will be enhanced by Dassault Systèmes, extracts morphological information from large retinal surfaces primarily through the development of AI-based algorithms. Integrating these measurements into biological markers that can be directly used by physicians is a major challenge in transferring data from the lab to the exam room."

Prof. Stanislas Lyonnais, Director, Institut Imagine
Institut Imagine is proud to be involved with Virtual Twin as a founding member in the strategic partnership between Dassault Systèmes and the IHU French Union. We are also honored to contribute our medical excellence and research in the field of rare diseases to the MEDITWIN project. The initial phase of the project, developed in collaboration with Dassault Systèmes and Inria, focuses on cardiology. The first project will utilize a personalized cardiovascular virtual twin to create a preoperative and intraoperative decision support system aimed at dramatically improving the mortality rate of newborns with congenital heart disease, particularly hypoplastic left heart syndrome; the second project, in collaboration with Dassault Systèmes and start-up company codoc, a startup company, to develop a tool to support the facilitation of multidisciplinary conferences on pediatric neurology. The project will use virtual twins of patients to aid in medical decision-making and the treatment of rare and intractable epilepsy, specifically Dravet syndrome. These two projects provide important opportunities for researchers and physicians to visualize, validate, understand, and predict before intervening with patients."

Prof. Alexis Bliss, Director, Paris Brain Institute, IHU ICM
We are pleased to be working with Dassault Systèmes and Inria through the IHU France Alliance to help realize the innovations that will create the healthcare of the future and thereby build the ecosystem of the healthcare industry." In MEDITWIN, the Paris Brain Institute will be able to: "create a virtual twin that will allow the Institute to embody its goals of efficiently utilizing medical data at different scales, modeling and predicting disease progression, early diagnosis, and building optimized care for each patient based on an accurate foundation;" and "create an environment that will allow the Institute to provide a more personalized and efficient medical care system for each and every patient, expertise in identifying Alzheimer's disease, vascular dementia, and epilepsy, as well as in analyzing data from patient groups."

Prof. Dr. Stefan Atem, President of IHU ICAN and Director of the Cardiovascular and Metabolic Diseases Research Unit, UMR 1166
The Virtual Twin technology opens up new possibilities for precision medicine and preventive medicine in cardiovascular metabolic diseases. Our goal is to predict each patient's future risk of developing cardiovascular disease based on individual risk factors, especially genetic signatures. To achieve this goal, we believe it is important to scale up our research, led by Dassault Systèmes and its participating partners.

Prof. Bertrand Calleu, Director, Institute of Thoracic Diseases, Nantes University Hospital
The Institute of Thoracic Diseases, affiliated with the University Hospital of Nantes, will work with engineers from Dassault Systèmes to develop a better predictive capability for heart attacks, a leading cause of death in industrialized countries. To achieve this goal, researchers will leverage data from the SAFIR group from the CHOPIN (CHOlesterol Personalized Innovation = Personalized Innovation on Cholestrol) study, a nationwide bridging study. This will include patients with familial hypercholesterolemia with or without heart disease. In a small pre-study study conducted in a population at very high risk of developing heart disease, clinical, multi-omics, and imaging data will be combined to create a virtual twin model that will then be validated in a larger population of heart disease patients."

Todor Yeriaskov, CEO, inHEART, Inc.
inHEART is honored to be at the forefront of digital healthcare transformation as part of MEDITWIN, which will focus on the prevention of acute cardiac events that kill more than 800,000 people annually, moving the healthcare system from acute complication management to complication prevention. The healthcare system will move away from acute complication management and treatment to complication prevention. In this, we believe that digital technology and AI will accelerate this process."

Arthur Delapalm, Co-Founder and CEO, codoc, Inc.
As codoc, we are very proud to develop one of the seven virtual twins in this project. As codoc, we are very proud to be developing one of the seven virtual twins in this project."

Stanley Durellman, CEO, Qairnel, Inc.
Qairnel is proud to be a part of the MEDITWIN project. Our virtual twin will allow us to simulate changes in the early stages of Alzheimer's disease. Through this project, we are putting this technology in the hands of healthcare professionals, who can then recommend management plans and treatment strategies optimized for each individual patient. By doing so, we can address a major public health challenge of the 21st century."

Lionel Nakasch, Co-Founder, Neurometers, Inc.
Neurometers aims to expand the medical use of electroencephalography (EEG) to quantify brain activity patterns that indicate states of cognition and awareness. Initially developed for healthy subjects and patients with communication difficulties, the results have been published in numerous scientific papers. Most recently, we discovered and published that this technique is highly effective in neurodegenerative diseases affecting cognitive function, such as Alzheimer's disease. For the first time, direct measures of cognitive function can be incorporated into a patient's regular follow-up, complementing neuropsychological tests and measurements of brain atrophy. This approach will also allow us to test the efficacy of new treatments. By participating in the MEDITWIN project, we aim to improve the quality of the algorithm by analyzing groups of patients whose EEGs were recorded using transitional methods."

About France 2030

France 2030 Investment Plan
Reflecting two goals: to transform in a sustainable way through technological innovation with respect to key sectors such as energy, automotive, and aerospace, and to position France not only as a future world player but also as a leader. From basic research to idea generation to the delivery of new products and services, France 2030 supports the entire innovation lifecycle up to industrialization.

Expansion of scale
In these strategic areas, 54 billion euros are available to ensure that each of our corporate, university, and research organizations will be able to accomplish transformation reliably and completely. Each organization will competitively address the environmental and attractiveness challenges of tomorrow's world and produce future leaders from our fields of excellence.
France 2030 has two cross-sectoral policies: following the principle of DNSH (Do No Significant Harm), 50% of the budget will be invested in decarbonizing the economy, while the remaining 50% will be invested in start-ups that develop innovations that do not impact the environment.

Joint Implementation
It will be planned and implemented in consultation with economic, academic, regional, and European stakeholders who will determine strategic direction and key initiatives. In order to receive a public grant, project leaders must submit a proposal following a fair and rigorous selective procedure.

Public-private initiative
It is led by the Directorate General for Investment on behalf of the Prime Minister and implemented by the French Ministry of Ecological Transition (ADEME), the French National Research Agency (ANR), the Public Investment Bank and the Banque de la Territoriale.

For more information on France 2030, please click here:france2030.gouv.fr | @SGPI_avenir

For more information about Dassault Systèmes' 3DEXPERIENCE platform, 3D design software, 3D digital mockups, product lifecycle management (PLM) solutions, and more, please visit our website.

Social accounts to connect with Dassault Systèmes

X (formerly Twitter):https://twitter.com/3dsjapan
Facebook:https://www.facebook.com/DassaultSystemesNippon
LinkedIn:https://jp.linkedin.com/company/dassaultsystemes
YouTube:https://www.youtube.com/user/3DSJapan

About Dassault Systèmes

As a 3DEXPERIENCE® Company, Dassault Systèmes plays a role in driving human progress, providing companies and individuals with a virtual collaboration environment that enables sustainable innovation.

Creating a virtual twin experience of the real world with the 3DEXPERIENCE platform and applications can redefine the process of product and service creation, manufacturing, and lifecycle management, resulting in a meaningful impact to make the world more sustainable. and have a meaningful impact on making the world more sustainable.
Together with its customers, Dassault Systèmes also promotes the Experience Economy, a human-centered economic activity for all people, including consumers, patients and citizens. Dassault Systèmes delivers value to more than 300,000 customers of all sizes and industries in over 150 countries.

3DEXPERIENCE, 3DS Logo, Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under the laws of France and registered with the Commercial Court Clerk's Division in Versailles under registration number 322 306 440, or of any of its subsidiaries in the United States or any other country. Dassault Systèmes is a trademark or registered trademark of Dassault Systèmes or its subsidiaries in the United States of America and other countries.

name of companyDassault Systèmes K.K.
EstablishmentJun. 1994
LocationThinkParkTower, 2-1-1 Osaki, Shinagawa-ku, Tokyo
representativePhilip Godb.
uniform resouce locatorhttps://www.3ds.com/ja(Japanese)
https://www.3ds.com(English)
PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。